, /PRNewswire/ -- Mozart Therapeutics, a clinical stage biopharmaceutical company focused on the development of CD8 Treg modulators for the treatment of autoimmune diseases, today presented new preclinical data on the Company's lead program, MTX-101. The data were reviewed during an oral presentation at the 2024 American Diabetes Association 84 Scientific Sessions, held June 21–24 in , Ph.D.
, Senior Vice President of Research at Mozart Therapeutics, presented data supporting the relevance of therapeutic modulation of the regulatory CD8 T cell network in autoimmune disease, including type 1 diabetes (T1D). Additionally, data from in vitro studies using T1D-derived PBMC demonstrate that treatment with MTX-101 increases the prevalence of CD8 Treg and that the functionality of CD8 Treg (i.e.
, activation and cytolytic capacity) can be restored in this autoimmune setting. "We are pleased to highlight this new preclinical data on MTX-101 in type 1 diabetes," said Dr. Crane.
"These data support the ability of MTX-101 to restore CD8 Treg function in autoimmune disease. We look forward to evaluating this candidate in patients with type 1 diabetes mellitus during Part B of our ongoing Phase 1 study". MTX-101 is a bispecific antibody targeting inhibitory KIR and CD8 expressed on regulatory CD8 T cells.
This autoimmune checkpoint inhibitor aims to restore the intrinsic functions of regulatory CD8 T cells, acting early in the autoimmune disease process to suppress and eliminate pathogeni.
